- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05344469
재발성 다발성 경화증 환자의 주사 치료를 평가하는 NIS (AIOLOS)
재발성 다발성 경화증 환자의 주사 치료(Ofatumumab, Glatiramer Acetate 및 Interferon β1)를 평가하는 비간섭 연구 [AIOLOS]
This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.
Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.
연구 개요
상태
정황
상세 설명
The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable or oral DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study.
Cohort 1: The prospective observational period per patient in the core part will be up to approx. two years from the time of consent (2 years +2 months visit window). If a patient re-consents to the extension part, then the prospective extension observational period will be additional approx. two years, resulting in a total observational period (prospectively for the core and extension part & retrospectively for the potential gap between core and extension part) of approx. 4 years (+ 2 month visit window).
Cohort 2: The prospective observational period per patient will be up to approx. two years from the time of consent (2 years + 2 months visit window).
The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion.
연구 유형
등록 (추정된)
연락처 및 위치
연구 연락처
- 이름: Novartis Pharmaceuticals
- 전화번호: +41613241111
- 이메일: novartis.email@novartis.com
연구 연락처 백업
- 이름: Novartis Pharmaceuticals
연구 장소
-
-
-
Aalen, 독일, 73433
- 모병
- Novartis Investigative Site
-
Altenholz, 독일, 24161
- 모병
- Novartis Investigative Site
-
Alzey, 독일, 55232
- 빼는
- Novartis Investigative Site
-
Augsburg, 독일, 86150
- 모병
- Novartis Investigative Site
-
Bamberg, 독일, 96047
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Bayreuth, 독일, 95445
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Bayreuth, 독일, 95444
- 모병
- Novartis Investigative Site
-
Bergneustadt, 독일, 51702
- 모병
- Novartis Investigative Site
-
Bergneustadt, 독일, 51702
- 빼는
- Novartis Investigative Site
-
Berlin, 독일, 12163
- 모병
- Novartis Investigative Site
-
Berlin, 독일, 12099
- 모병
- Novartis Investigative Site
-
Berlin, 독일, 14057
- 모병
- Novartis Investigative Site
-
Berlin, 독일, 10437
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Berlin, 독일, 10713
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Berlin, 독일, 12099
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Berlin, 독일, 12099
- 완전한
- Novartis Investigative Site
-
Berlin, 독일, 12351
- 완전한
- Novartis Investigative Site
-
Berlin, 독일, 13357
- 빼는
- Novartis Investigative Site
-
Berlin, 독일, 14169
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Bochum, 독일, 44791
- 모병
- Novartis Investigative Site
-
Bochum, 독일, 44787
- 모병
- Novartis Investigative Site
-
Bogen, 독일, 94327
- 모병
- Novartis Investigative Site
-
Bonn, 독일, 53111
- 모병
- Novartis Investigative Site
-
Braunschweig, 독일, 38100
- 모병
- Novartis Investigative Site
-
Bremen, 독일, 28195
- 완전한
- Novartis Investigative Site
-
Böblingen, 독일, 71032
- 모병
- Novartis Investigative Site
-
Chemnitz, 독일, 09117
- 모병
- Novartis Investigative Site
-
Coburg, 독일, 96450
- 모병
- Novartis Investigative Site
-
Crailsheim, 독일, 74564
- 모병
- Novartis Investigative Site
-
Dessau, 독일, 06846
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Dillingen Saar, 독일, 66763
- 모병
- Novartis Investigative Site
-
Dortmund, 독일, 44137
- 모병
- Novartis Investigative Site
-
Dresden, 독일, 01067
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Dresden, 독일, 01097
- 모병
- Novartis Investigative Site
-
Duisburg, 독일, 47138
- 모병
- Novartis Investigative Site
-
Duisburg, 독일, 47138
- 빼는
- Novartis Investigative Site
-
Düsseldorf, 독일, 40211
- 모병
- Novartis Investigative Site
-
Düsseldorf, 독일, 40625
- 모병
- Novartis Investigative Site
-
Düsseldorf, 독일, 40211
- 완전한
- Novartis Investigative Site
-
Eisleben Lutherstadt, 독일, 06295
- 모병
- Novartis Investigative Site
-
Eltville, 독일, 65343
- 모병
- Novartis Investigative Site
-
Erbach im Odenwald, 독일, 64711
- 모병
- Novartis Investigative Site
-
Erfurt, 독일, 99099
- 모병
- Novartis Investigative Site
-
Erfurt, 독일, 99096
- 모병
- Novartis Investigative Site
-
Erlangen, 독일, 91054
- 모병
- Novartis Investigative Site
-
Essen, 독일, 45257
- 모병
- Novartis Investigative Site
-
Essen, 독일, 45138
- 모병
- Novartis Investigative Site
-
Fulda, 독일, 36037
- 모병
- Novartis Investigative Site
-
Fulda, 독일, 36037
- 완전한
- Novartis Investigative Site
-
Giessen, 독일, 35392
- 모병
- Novartis Investigative Site
-
Gladenbach, 독일, 35075
- 모병
- Novartis Investigative Site
-
Hagen, 독일, 58095
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Hamburg, 독일, 20249
- 모병
- Novartis Investigative Site
-
Hamburg, 독일, 22179
- 모병
- Novartis Investigative Site
-
Hanover, 독일, 30625
- 모병
- Novartis Investigative Site
-
Höxter, 독일, 37671
- 모병
- Novartis Investigative Site
-
Itzehoe, 독일, 25524
- 빼는
- Novartis Investigative Site
-
Kaiserslautern, 독일, 67655
- 완전한
- Novartis Investigative Site
-
Karlsruhe, 독일, 76133
- 모병
- Novartis Investigative Site
-
Karlsruhe, 독일, 76133
- 빼는
- Novartis Investigative Site
-
Lünen, 독일, 44534
- 빼는
- Novartis Investigative Site
-
Magdeburg, 독일, 39104
- 모병
- Novartis Investigative Site
-
Marburg, 독일, 35037
- 완전한
- Novartis Investigative Site
-
Merzig, 독일, 66663
- 모병
- Novartis Investigative Site
-
Mettmann, 독일, 40822
- 완전한
- Novartis Investigative Site
-
Minden, 독일, 32429
- 완전한
- Novartis Investigative Site
-
Montabaur, 독일, 56410
- 완전한
- Novartis Investigative Site
-
Muenster-Hiltrup, 독일, 48165
- 모병
- Novartis Investigative Site
-
Mülheim, 독일, 45468
- 빼는
- Novartis Investigative Site
-
München, 독일, 80939
- 모병
- Novartis Investigative Site
-
München, 독일, 81675
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Münster, 독일, 48149
- 모병
- Novartis Investigative Site
-
Neuruppin, 독일, 16816
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Nuremberg, 독일, 90491
- 빼는
- Novartis Investigative Site
-
Oldenburg, 독일, 26121
- 모병
- Novartis Investigative Site
-
Osnabrück, 독일, 49074
- 모병
- Novartis Investigative Site
-
Pforzheim, 독일, 75172
- 모병
- Novartis Investigative Site
-
Potsdam, 독일, 14471
- 완전한
- Novartis Investigative Site
-
Remscheid, 독일, 42853
- 모병
- Novartis Investigative Site
-
Rostock, 독일, 18057
- 완전한
- Novartis Investigative Site
-
Rüdersdorf, 독일, 15562
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Rülzheim, 독일, 76761
- 모병
- Novartis Investigative Site
-
Salzatal, 독일, 06198
- 모병
- Novartis Investigative Site
-
Schiltach, 독일, 77761
- 모병
- Novartis Investigative Site
-
Schneverdingen, 독일, 29640
- 모병
- Novartis Investigative Site
-
Siegen, 독일, 57076
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Siegen, 독일, 57076
- 모병
- Novartis Investigative Site
-
Sinsheim, 독일, 74889
- 모병
- Novartis Investigative Site
-
Stadtroda, 독일, 07646
- 모병
- Novartis Investigative Site
-
Stuttgart, 독일, 70176
- 모병
- Novartis Investigative Site
-
Stuttgart, 독일, 70174
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Stuttgart, 독일, 70182
- 완전한
- Novartis Investigative Site
-
Tirschenreuth, 독일, 95643
- 모병
- Novartis Investigative Site
-
Trier, 독일, 54292
- 모병
- Novartis Investigative Site
-
Tübingen, 독일, 72076
- 모병
- Novartis Investigative Site
-
Velbert, 독일, 42551
- 모병
- Novartis Investigative Site
-
Weil der Stadt, 독일, 71263
- 모병
- Novartis Investigative Site
-
Witten, 독일, 58452
- 모병
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Albstadt, Baden-Wurttemberg, 독일, 72458
- 모병
- Novartis Investigative Site
-
Hettingen, Baden-Wurttemberg, 독일, 72513
- 모병
- Novartis Investigative Site
-
Hettingen, Baden-Wurttemberg, 독일, 72513
- 완전한
- Novartis Investigative Site
-
Mannheim, Baden-Wurttemberg, 독일, 68163
- 모병
- Novartis Investigative Site
-
Nagold, Baden-Wurttemberg, 독일, 72202
- 모병
- Novartis Investigative Site
-
Schwetzingen, Baden-Wurttemberg, 독일, 68723
- 모병
- Novartis Investigative Site
-
Schwäbisch Hall, Baden-Wurttemberg, 독일, 74523
- 모병
- Novartis Investigative Site
-
-
Bavaria
-
Bamberg, Bavaria, 독일, 96052
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Dillingen an der Donau, Bavaria, 독일, 89407
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Munich, Bavaria, 독일, 81241
- 빼는
- Novartis Investigative Site
-
Munich, Bavaria, 독일, 81829
- 빼는
- Novartis Investigative Site
-
Neuburg A.d. Donau, Bavaria, 독일, 86633
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Regensburg, Bavaria, 독일, 93059
- 빼는
- Novartis Investigative Site
-
Unterhaching, Bavaria, 독일, 82008
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Untermeitingen, Bavaria, 독일, 86836
- 모병
- Novartis Investigative Site
-
Wolfratshausen, Bavaria, 독일, 82515
- 빼는
- Novartis Investigative Site
-
-
Brandenburg
-
Falkensee, Brandenburg, 독일, 14612
- 빼는
- Novartis Investigative Site
-
-
Hesse
-
Bad Homburg, Hesse, 독일, 61348
- 모병
- Novartis Investigative Site
-
Frankfurt am Main, Hesse, 독일, 65929
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Frankfurt am Main, Hesse, 독일, 60313
- 완전한
- Novartis Investigative Site
-
Marburg, Hesse, 독일, 35043
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
-
Lower Saxony
-
Hanover, Lower Saxony, 독일, 30161
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Hanover, Lower Saxony, 독일, 30449
- 완전한
- Novartis Investigative Site
-
Wildeshausen, Lower Saxony, 독일, 27793
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, 독일, 50935
- 모병
- Novartis Investigative Site
-
Cologne, North Rhine-Westphalia, 독일, 51063
- 빼는
- Novartis Investigative Site
-
Dortmund, North Rhine-Westphalia, 독일, 44287
- 모병
- Novartis Investigative Site
-
Düsseldorf, North Rhine-Westphalia, 독일, 40225
- 모병
- Novartis Investigative Site
-
Essen, North Rhine-Westphalia, 독일, 45134
- 빼는
- Novartis Investigative Site
-
Gelsenkirchen, North Rhine-Westphalia, 독일, 45894
- 모병
- Novartis Investigative Site
-
Meerbusch, North Rhine-Westphalia, 독일, 40667
- 모병
- Novartis Investigative Site
-
Münster, North Rhine-Westphalia, 독일, 48165
- 빼는
- Novartis Investigative Site
-
Oer-Erkenschwick, North Rhine-Westphalia, 독일, 45739
- 빼는
- Novartis Investigative Site
-
Siegen, North Rhine-Westphalia, 독일, 57072
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Ingelheim, Rhineland-Palatinate, 독일, 55218
- 빼는
- Novartis Investigative Site
-
-
Saarland
-
Saarlouis, Saarland, 독일, 66740
- 빼는
- Novartis Investigative Site
-
-
Saxony
-
Chemnitz, Saxony, 독일, 09117
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
Dresden, Saxony, 독일, 01307
- 모병
- Novartis Investigative Site
-
Görlitz, Saxony, 독일, 02828
- 모병
- Novartis Investigative Site
-
Leipzig, Saxony, 독일, 04103
- 완전한
- Novartis Investigative Site
-
Leipzig, Saxony, 독일, 04315
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Altmark, Saxony-Anhalt, 독일, 39629
- 빼는
- Novartis Investigative Site
-
Halle, Saxony-Anhalt, 독일, 06120
- 모병
- Novartis Investigative Site
-
Halle, Saxony-Anhalt, 독일, 06112
- 모병
- Novartis Investigative Site
-
-
Thuringia
-
Altenburg, Thuringia, 독일, 04600
- 완전한
- Novartis Investigative Site
-
Altenburg, Thuringia, 독일, 04600
- 빼는
- Novartis Investigative Site
-
Jena, Thuringia, 독일, 07740
- 모병
- Novartis Investigative Site
-
Mühlhausen, Thuringia, 독일, 99974
- 모집하지 않고 적극적으로
- Novartis Investigative Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
patients with planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment
설명
Cohort 1 Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study
- Male or female patients aged ≥18 years at enrollment
- Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
- RMS with active disease as defined by Lublin et al. (2014)
- Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment
- Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
- Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment
Cohort 2 Inclusion Criteria:
-
Signed informed consent must be obtained prior to participation,
-
Male or female patients aged ≥18 years at enrollment,
-
Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),
-
RMS with active disease as defined by Lublin et al. (2014) ,
-
Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,
-
Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),
-
Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:
- Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab
- IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients
Cohort 1 Exclusion Criteria:
- Patients being treated outside of the approved label
- > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment
- Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7)
- Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
- Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
- EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab
Cohort 2 Exclusion Criteria:
- Patients being treated outside of the approved label,
- >5 years since first symptom(s) (leading to MS diagnosis) at enrollment,
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab,
- Patients being previously enrolled in cohort 1 are not eligible to be enrolled into cohort 2
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Ofatumumab
Patients treated with ofatumumab |
There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled. |
|
Standard of Care (SoC)
Patients treated with either interferon β1 (IFN-β1), glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF) or diroximel fumarate (DRF) |
There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled. There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled. There is no treatment allocation. Patients administered teriflunomide by prescription that have started as routine medical treatment will be enrolled. There is no treatment allocation. Patients administered dimethyl fumarate (DMF) by prescription that have started as routine medical treatment will be enrolled. There is no treatment allocation. Patients administered diroximel fumarate (DRF) by prescription that have started as routine medical treatment will be enrolled. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients who continue to receive their baseline treatment
기간: Month 24
|
Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)] |
Month 24
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of patients who continue to receive their baseline treatment
기간: Month 12
|
Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)] |
Month 12
|
|
Time to event analysis for retention time on baseline treatment
기간: From Baseline to event, up to 24 months
|
Time-to-event analysis for retention time on baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)] |
From Baseline to event, up to 24 months
|
|
Impact of first-line treatment on health economy
기간: Baseline, month 6, month 12, month 18 and month 24
|
Mean annual health care resource utilization cost, annual direct medical costs, annual direct nonmedical costs and annual indirect costs as measured by MS Health Resource Utilization Survey [MS-HRS] MS-HRS is a 24-item questionnaire covers societal resource use, regardless of the issue of reimbursement, as well as impact of the disease on work, family and leisure. With the help of this questionnaire a monetary value can be assigned to e.g. the stage of MS, a relapse or a therapy. |
Baseline, month 6, month 12, month 18 and month 24
|
|
Fatigue Symptoms and Impact Questionnaire-RMS
기간: Baseline, month 3, month 6, month 12, month 18, month 24
|
Fatigue Symptoms and Impact Questionnaire-RMS [FSIQ-RMS] The FSIQ-RMS comprises 20 items organized in a conceptual framework with 2 symptom domains (energy, muscle weakness) and 7 impact domains (daily activities, cognition, emotions, physical impact, self-care, sleep, social impact) in order to measure fatigue symptoms and impacts in relapsing multiple sclerosis. A scoring algorithm standardizes scores on both the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating more severe symptoms and impacts. There is no single summary score across the FSIQ-RMS instrument, but rather 1 symptoms score and 3 impacts subdomain scores. |
Baseline, month 3, month 6, month 12, month 18, month 24
|
|
Patient Health Questionnaire 8 [PHQ-8]
기간: Baseline, month 3, month 6, month 12, month 18, month 24
|
The PHQ-8 is a valid diagnostic and severity measure for depressive disorders. It consists of eight items, each of which is scored 0 to 3, providing a 0 to 24 severity score. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively. |
Baseline, month 3, month 6, month 12, month 18, month 24
|
|
Generalized Anxiety Disorder Scale 7 [GAD-7]
기간: Baseline, month 3, month 6, month 12, month 18, month 24
|
The GAD-7 is a validated 7-item anxiety scale to diagnose generalized anxiety disorder. Each of the items is scored 0 to 3, providing a 0 to 21 severity score. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively |
Baseline, month 3, month 6, month 12, month 18, month 24
|
|
Multiple Sclerosis Impact Scale 29 v2
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
|
In this non-interventional study only the nine psychological items will be used to allow conclusions regarding the mental health status of patients with mildly active multiple sclerosis. In its version 2, each item of the MSIS-29 provides four response alternatives, which are rated as 1 to 4. Accordingly, the psychological scale will be described by a raw score between 9 and 36, which will be transformed into a final score between 0 (no impact) and 100 (extreme impact). |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
|
|
Quality of Life in Neurological Disorders [NeuroQoL]
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
|
n this non-interventional study the following items will be used: Anxiety, Depression, Ability to Participate in Social Roles and Activities, Positive Affect and Well-Being & Sleep Disturbance. Each response option is assigned a value (e.g.,1=Not at all) and total summed raw score for each respondent are calculated. The total raw score is then translated into a T-score for each participant by using conversion tables. These Tscore are standardized scores with a mean of 50 and a standard deviation (SD) of 10. |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
|
|
MS Treatment Concerns Questionnaire [MSTCQ]
기간: Baseline, month 3, month 6, month 12, month 18, month 24
|
MS Treatment Concerns Questionnaire [MSTCQ] is used to assess participants' satisfaction with their treatment injections. The MSTCQ includes 20 items pertaining satisfaction with the injection system (including issues related to use of the device and preparation of the medication for injection), and AEs related to the patient MS treatment. All questions have a 5-point response choice, with the responses scored between 1-5. The MSTCQ scores are formed as the sum of all scores. The maximum total score is 100. Lower scores indicate a better state. |
Baseline, month 3, month 6, month 12, month 18, month 24
|
|
Expanded disability status scale (EDSS)
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
EDSS is a widely used and accepted instrument to evaluate disability status at a given time and, longitudinally, to assess accumulation of disability in clinical studies in MS. The EDSS scale consists of scores in each of seven functional systems (FSs) and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, and Cerebral functions (Fatigue contributes) |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Time to onset of confirmed disability worsening (CDW)
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
Time to onset of confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Proportion of patients with confirmed disability worsening (CDW)
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
Proportion of patients with confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Time to onset of confirmed disability improvement (CDI)
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
Time to onset of confirmed disability improvement (CDI) defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Proportion of patients with CDI
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
Proportion of patients with CDI defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
T1 Gd-enhancing lesions per brain
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
T1 Gd-enhancing lesions per brain to be measured |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Annualized T2 lesion rate
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
New or enlarging T2 lesions per brain and per year (annualized T2 lesion rate) |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Presence of spinal cord lesions
기간: Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24
|
Proportion of patients with spinal cord lesions present |
Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24
|
|
Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator.
기간: Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator. NEDA3 is defined as no 3mCDP, no confirmed MS relapse and no new or enlarging T2 lesions on any MRI scan compared to baseline |
Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
|
|
Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs
기간: Up to 24 months
|
Proportion of patients with no clinical disease activity measured by relapse and disease progression and no discontinuation of current treatment due to AEs (excluding pregnancies) and lack of effectiveness |
Up to 24 months
|
|
Annualized relapse rate
기간: Up to 24 months
|
Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year. Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection. |
Up to 24 months
|
|
Time to first relapse
기간: Up to 24 months
|
Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection. |
Up to 24 months
|
|
Proportion of relapse free patients
기간: Up to 24 months
|
Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection. |
Up to 24 months
|
|
Serum NfL levels
기간: Baseline, month 6, month 12, month 18 and month 24
|
sNfL levels |
Baseline, month 6, month 12, month 18 and month 24
|
|
Proportion of patients with low or elevated sNfL levels
기간: Baseline, month 6, month 12, month 18 and month 24
|
Proportion of patients with low or elevated sNfL levels |
Baseline, month 6, month 12, month 18 and month 24
|
|
Association of selected effectiveness and PRO outcomes with sNfL levels
기간: Baseline, month 6, month 12, month 18 and month 24
|
Association of higher or lower sNfL concentrations with differences in e.g. disease activity, functional status, quality of life, and other PRO-based measures |
Baseline, month 6, month 12, month 18 and month 24
|
|
Reasons for treatment decisions
기간: Up to 24 months
|
Number of participants by reasons for treatment decisions |
Up to 24 months
|
|
Number of patients and reasons for discontinuation of treatment
기간: Up to 24 months
|
Number of patients and reasons for discontinuation of treatment classified by category:
|
Up to 24 months
|
|
Proportion of patients who continue to receive their subsequent treatment
기간: Up to 24 months
|
Proportion of patients who, at a given time over the observational period, continue to receive their subsequent treatment |
Up to 24 months
|
|
Reasons for and number of treatment interruptions per patient
기간: Up to 24 months
|
Reasons for and number of treatment interruptions per patient to be collected |
Up to 24 months
|
|
Duration of treatment interruptions per patient
기간: Up to 24 months
|
Duration of treatment interruptions per patient to be collected |
Up to 24 months
|
|
Number of patients with treatment interruptions
기간: Up to 24 months
|
Number of patients with treatment interruptions to be collected |
Up to 24 months
|
|
Proportion of drug-related adverse events (AEs)
기간: Up to 24 months
|
Proportion of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions) |
Up to 24 months
|
|
Persistence of drug-related adverse events (AEs)
기간: Up to 24 months
|
Persistence of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions, influenza-like symptoms) |
Up to 24 months
|
|
Specific safety assessment of injection related AEs
기간: Up to 24 months
|
Specific safety assessment of injection related AEs. (i.e. injection site reaction AEs vs. injection systemic reaction AEs) summarized by providing the number and percentage of patients with each of the symptoms and pre-specified grouping of symptoms as well as overall. |
Up to 24 months
|
|
Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons
기간: Up to 24 months
|
Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons |
Up to 24 months
|
|
Proportion of sites that share the standardized MRI report form with their radiological colleagues
기간: Baseline, month 6, month 12, month 18 and month 24
|
Proportion of sites that share the standardized MRI report form with their radiological colleagues |
Baseline, month 6, month 12, month 18 and month 24
|
|
Proportion of standardized MRI report forms and conventional radiologists' reports
기간: Baseline, month 6, month 12, month 18 and month 24
|
Proportion of standardized MRI report forms and conventional radiologists' reports |
Baseline, month 6, month 12, month 18 and month 24
|
|
Effect of standardized MRI report form on completeness of lesion documentation
기간: Baseline, month 6, month 12,1 month 8 and month 24
|
Proportion of complete MRI lesion documentation using the standardized MRI form versus non-standardized documentation. |
Baseline, month 6, month 12,1 month 8 and month 24
|
|
Physician's view on added value of standardized MRI report form over conventional radiologists' reports
기간: Baseline, month 6, month 12, month 18 and month 24
|
Proportion of physicians who rate the added value of the standardized MRI report form higher than that of conventional radiologists' reports |
Baseline, month 6, month 12, month 18 and month 24
|
|
Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue
기간: Month 6,month 12, month 18 and month 24
|
Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue |
Month 6,month 12, month 18 and month 24
|
|
Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months
기간: Month 6,month 12, month 18 and month 24
|
Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months |
Month 6,month 12, month 18 and month 24
|
|
Perceived value of PRO and sNfL result visualizations from the perspective of both patient and treating physician on patient-physician dialogue and shared decision making
기간: Month 6,month 12, month 18 and month 24
|
Proportion of patients and physicians who perceive an added value of PRO and sNfL result visualizations on patient-physician dialogue and shared decision making |
Month 6,month 12, month 18 and month 24
|
|
Age of male and female participants
기간: Baseline
|
Age |
Baseline
|
|
Number of previous MS relapses of male and female participants
기간: Baseline
|
Number of MS relapses in the 24 months prior baseline |
Baseline
|
|
Serum NfL levels of male and female patients
기간: Baseline, month 6, month 12, month 18 and month 24
|
sNfL levels |
Baseline, month 6, month 12, month 18 and month 24
|
|
Proportion of male and female patients who continue to receive their baseline treatment
기간: Month 12, Month 24
|
Proportion of male and female patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)] |
Month 12, Month 24
|
|
Annualized relapse rate of male and female patients
기간: Up to 24 months
|
Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year of male and female participants |
Up to 24 months
|
|
Reasons for treatment decisions of male and female patients
기간: Up to 24 months
|
Number of male and female participants by reasons for treatment decisions |
Up to 24 months
|
|
Quality of Life in Neurological Disorders [NeuroQoL] of male and female patients
기간: Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24
|
T-scores of male and female patients.
|
Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Novartis Pharmaceuticals, Novartis Pharmaceuticals
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- COMB157GDE02
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .